Stryker (NYSE:SYK) Stock: Insider Ronda Stryker Sells 550,000 Shares

Stryker Corporation (NYSE:SYK) Director Ronda Stryker sold 550,000 shares of the firm’s stock in a transaction dated Friday, November 6th. The shares were sold at an average price of $325.32, for a total value of $178,926,000.00. Following the completion of the transaction, the director owned 1,701,375 shares in the company, valued at approximately $553,491,315. This represents a 24.43% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Stryker Stock Down 0.5%

NYSE SYK opened at $324.00 on Wednesday. The company has a current ratio of 2.18, a quick ratio of 1.30 and a debt-to-equity ratio of 0.60. The company has a market cap of $123.34 billion, a price-to-earnings ratio of 34.50, a PEG ratio of 2.24 and a beta of 0.78. The company has a 50 day moving average of $292.25 and a 200-day moving average of $323.23. Stryker Corporation has a 1-year low of $267.00 and a 1-year high of $389.33.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, October 29th. The medical technology company reported $3.52 EPS for the quarter, missing analysts’ consensus estimates of $3.55 by ($0.03). The company had revenue of $6.52 billion for the quarter, compared to the consensus estimate of $6.62 billion. Stryker had a return on equity of 23.74% and a net margin of 13.78%. Stryker’s revenue was up 7.6% on a year-over-year basis. During the same quarter last year, the business earned $3.19 EPS. On average, equities research analysts expect that Stryker Corporation will post 14.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on SYK shares. Canaccord Genuity Group downgraded shares of Stryker from a “buy” rating to a “hold” rating and cut their price target for the stock from $385.00 to $300.00 in a report on Friday, October 30th. Jefferies Financial Group dropped their target price on shares of Stryker from $440.00 to $405.00 and set a “buy” rating for the company in a report on Tuesday, September 22nd. The Goldman Sachs Group reduced their price target on shares of Stryker from $363.00 to $339.00 and set a “neutral” rating on the stock in a research note on Tuesday, July 14th. Citizens Jmp decreased their price target on shares of Stryker from $400.00 to $390.00 and set a “market outperform” rating on the stock in a report on Friday, October 30th. Finally, TD Cowen lowered their price objective on shares of Stryker from $298.00 to $290.00 and set a “hold” rating for the company in a research report on Friday, October 30th. Twenty-one research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $342.19.

Institutional Trading of Stryker

Hedge funds have recently made changes to their positions in the company. Private Advisor Group LLC raised its holdings in Stryker by 92.0% in the 3rd quarter. Private Advisor Group LLC now owns 25,401 shares of the medical technology company’s stock valued at $6,995,000 after buying an additional 12,169 shares during the last quarter. Tyche Wealth Partners LLC grew its holdings in Stryker by 41.0% during the 3rd quarter. Tyche Wealth Partners LLC now owns 1,382 shares of the medical technology company’s stock worth $381,000 after acquiring an additional 402 shares during the last quarter. Checchi Capital Advisers LLC increased its position in Stryker by 6.2% in the 3rd quarter. Checchi Capital Advisers LLC now owns 3,313 shares of the medical technology company’s stock valued at $912,000 after acquiring an additional 192 shares during the period. Bluebird Wealth Management LLC increased its position in Stryker by 1.2% in the 3rd quarter. Bluebird Wealth Management LLC now owns 3,552 shares of the medical technology company’s stock valued at $978,000 after acquiring an additional 42 shares during the period. Finally, Banco BTG Pactual S.A. acquired a new position in Stryker in the 3rd quarter valued at approximately $380,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Company Profile

Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings. The company’s products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.